4.095
7.14%
-0.315
Puma Biotechnology Inc stock is currently priced at $4.095, with a 24-hour trading volume of 1.52M.
It has seen a -7.14% decreased in the last 24 hours and a -20.79% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $4.49 pivot point. If it approaches the $4.00 support level, significant changes may occur.
Previous Close:
$4.41
Open:
$4.4
24h Volume:
1.52M
Market Cap:
$197.54M
Revenue:
$235.64M
Net Income/Loss:
$21.59M
P/E Ratio:
-81.90
EPS:
-0.05
Net Cash Flow:
$14.37M
1W Performance:
-14.86%
1M Performance:
-20.79%
6M Performance:
+6.36%
1Y Performance:
+44.19%
Puma Biotechnology Inc Stock (PBYI) Company Profile
Name
Puma Biotechnology Inc
Sector
Industry
Phone
424-248-6500
Address
10880 Wilshire Boulevard, Suite 2150, Los Angeles, CA
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-28-21 | Upgrade | Citigroup | Neutral → Buy |
Jun-25-20 | Resumed | BofA/Merrill | Underperform |
Oct-08-19 | Downgrade | Goldman | Neutral → Sell |
May-10-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
May-10-19 | Downgrade | Citigroup | Buy → Neutral |
Jan-17-19 | Initiated | Leerink Partners | Mkt Perform |
Jan-03-19 | Downgrade | Guggenheim | Buy → Neutral |
Nov-19-18 | Upgrade | Goldman | Sell → Neutral |
Nov-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
Nov-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
Sep-17-18 | Initiated | Goldman | Sell |
May-11-18 | Reiterated | Stifel | Buy |
Nov-10-17 | Reiterated | Citigroup | Buy |
Nov-10-17 | Reiterated | RBC Capital Mkts | Sector Perform |
Oct-02-17 | Reiterated | Stifel | Buy |
Sep-11-17 | Reiterated | Credit Suisse | Outperform |
Jul-10-17 | Resumed | Leerink Partners | Outperform |
Jun-06-17 | Reiterated | RBC Capital Mkts | Sector Perform |
May-25-17 | Reiterated | RBC Capital Mkts | Sector Perform |
Mar-02-17 | Reiterated | RBC Capital Mkts | Sector Perform |
View All
Puma Biotechnology Inc Stock (PBYI) Latest News
Pfizer Unit Wins $107.5M Patent Verdict Against AstraZeneca - Law360
Law360
Puma Biotech surges amid Wyeth victory in Tagrisso patent case (NASDAQ:PBYI) - Seeking Alpha
Seeking Alpha
Puma Biotech gets EU panel nod for breast cancer drug - Yahoo News UK
Yahoo News UK
Puma Biotechnology Inc (PBYI) may enjoy gains as insiders got busy in the recent days – Knox Daily - Knox Daily
Knox Daily
Should You Be Concerned About Puma Biotechnology, Inc.'s (NASDAQ:PBYI) ROE? - Yahoo New Zealand News
Yahoo New Zealand News
Puma Biotech gets EU panel nod for breast cancer drug - Yahoo News UK
Yahoo News UK
Puma Biotechnology Inc Stock (PBYI) Financials Data
Puma Biotechnology Inc (PBYI) Revenue 2024
PBYI reported a revenue (TTM) of $235.64 million for the quarter ending December 31, 2023, a +3.34% rise year-over-year.
Puma Biotechnology Inc (PBYI) Net Income 2024
PBYI net income (TTM) was $21.59 million for the quarter ending December 31, 2023, a +1.08M% increase year-over-year.
Puma Biotechnology Inc (PBYI) Cash Flow 2024
PBYI recorded a free cash flow (TTM) of $14.37 million for the quarter ending December 31, 2023, a +190.79% increase year-over-year.
Puma Biotechnology Inc (PBYI) Earnings per Share 2024
PBYI earnings per share (TTM) was $0.45 for the quarter ending December 31, 2023, a +104.55% growth year-over-year.
Puma Biotechnology Inc Stock (PBYI) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
NOUGUES MAXIMO F | Chief Financial Officer |
Jan 03 '24 |
Sale |
4.49 |
15,682 |
70,348 |
128,666 |
Ludwig Jeffrey Jerome | Chief Commercial Officer |
Jan 03 '24 |
Sale |
4.49 |
12,956 |
58,119 |
99,970 |
HUNT DOUGLAS M | See Remarks |
Jan 03 '24 |
Sale |
4.49 |
8,358 |
37,493 |
103,319 |
Wong Alvin F | Chief Scientific Officer |
Jan 03 '24 |
Sale |
4.49 |
7,733 |
34,689 |
98,214 |
Wong Alvin F | Chief Scientific Officer |
Dec 04 '23 |
Sale |
3.76 |
280 |
1,053 |
97,934 |
MILLER MICHAEL PATRICK | Director |
Nov 07 '23 |
Sale |
2.83 |
25,000 |
70,802 |
43,358 |
AUERBACH ALAN H | President and CEO |
Jul 03 '23 |
Sale |
3.31 |
60,698 |
200,983 |
6,978,343 |
NOUGUES MAXIMO F | Chief Financial Officer |
Jul 03 '23 |
Sale |
3.31 |
14,680 |
48,608 |
144,348 |
Ludwig Jeffrey Jerome | Chief Commercial Officer |
Jul 03 '23 |
Sale |
3.31 |
12,103 |
40,075 |
112,926 |
HUNT DOUGLAS M | See Remarks |
Jul 03 '23 |
Sale |
3.31 |
7,809 |
25,857 |
111,677 |
About Puma Biotechnology Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous)). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Cap:
|
Volume (24h):